Inhalation Sciences Sweden AB, a leader in inhalation research technologies, faced a challenging 2024 marked by slow customer decision-making and financial constraints. Despite these hurdles, the company remains optimistic about its future, driven by strategic initiatives and innovative product developments.

The CEO's statement highlights the persistent interest from customers, albeit with delayed decision-making and financial challenges in their development projects. These factors contributed to a decline in turnover and sales for the year. However, the company anticipates improvements in 2025, with a stronger focus on converting its SEK 40 million pipeline into revenue.

A key highlight for Inhalation Sciences in 2024 was the collaboration with the US FDA on the DissolvIt module. The initial feedback has been promising, and the company is eager to publish the completed study, expecting it to boost sales. Furthermore, the launch of an upgraded XposeAli module with Microperfusion is set to address the needs of biological customers, enhancing the company's unique position in the In Vitro-In Vivo Correlation (IVIVC) market.

Financially, the company ended 2024 with a stable cash position, though additional capital is needed to support its growth plans. The Board is actively exploring various financing options to ensure the company's strategic objectives are met.

Considering the current market conditions and the company's strategic initiatives, investors might consider holding their positions. The potential for growth in 2025, driven by new product launches and strategic partnerships, presents a compelling case for maintaining investment in Inhalation Sciences.